



Future Science Group

CATALOGUE 2017

JOURNALS | SERVICES | eCOMMUNITIES

WELCOME

I am delighted to introduce our catalogue comprising everything you need to know about Future Science Group (FSG).

Our journals, publishing solutions and digital sites continue to service a mixed professional audience, whether authors, librarians, sponsors, or various other science and medical professionals.

The last year has been an exciting period of growth for FSG, with a rise of over 160,000 full-text downloads (more than 1.1 million in the last 12 months). We have also been very active with Open Access – our two recent journal additions, *Concussion* (P.9) and *Future Science OA* (P.14), continue to shine. And we're excited about our two latest journal launches; the *International Journal of Pharmacokinetics* (P.7) serves the needs of all professionals within the field of drug development, while the *Journal of 3D Printing in Medicine* (P.7), very much in keeping with our ethos, focuses on a truly cutting-edge field of medicine.

Although growth is great, commitment to our communities is always dear to us. Closely linked to the *Journal of 3D Printing in Medicine*, 3DMedNet (P.34) is a key addition to our eCommunities, including Bioanalysis Zone (over 8000 members), Oncology Central (more than 5000 members) and Neurology Central; all three of which have launched their very own apps.

Finally, we are committed to offering all of our customers the very best in customer service. Our recent partnership with Kudos will help authors increase the impact and reach of their research, and we are producing more and more webinars (see P.35).

I look forward to working with you in the year ahead.

Phil Garner

Managing Director, Future Science Group

CONTENTS

JOURNALS.....	4	SERVICES	18	eCOMMUNITIES.....	30
Our Journal Portfolio	5	New Website	19	Sponsorship & Advertising	35
Future Medicine At-A-Glance ..	6	Our Publishing Process	20		
Future Science At-A-Glance	7	Making The Most Of Your Article	22		
Future Medicine Journals	8	Open Access	23		
Future Science Journals	13	Accelerated Publication.....	24		
Information For Librarians	16	How To Publish With FSG	28		
Institutional Trials.....	17				

| Journals



OUR JOURNAL PORTFOLIO

FSG publishes a constantly expanding group of journals in cutting-edge areas of postgenomic scientific and medical information. Many of our titles are indexed on MEDLINE, Thomson's Science Citation Index Expanded, EMBASE, Chemical Abstracts and Scopus. While the topics are diverse, all publications are:

Original and Timely – blending commissioned and unsolicited content, whether reviews, research or commentaries, to ensure that readers are kept comprehensively updated on the latest advances and techniques in bioscience and clinical practice, whatever their discipline.


Easy-To-Read – we have produced a specially designed reader-friendly layout for all content to speed up learning and save time.

Visible and Accessible Globally – to ensure 24/7 access, all our titles are hosted by Atypon – a market leader in content management platforms.

FUTURE MEDICINE AT-A-GLANCE

Journal	MEDLINE-indexed	Impact Factor (2015)	Average Abstract Views (per month)	Acceptance Rate (2016)	Page
Biomarkers in Medicine	Yes	2.179	11,054	~30%	9
Breast Cancer Management	No	N/A	1431	~70%	9
CNS Oncology	Yes	N/A	3302	>80%	9
Colorectal Cancer	No	N/A	961	>80%	9
Concussion 	No	N/A	486	>80%	9
Epigenomics	Yes	4.044	13,495	~70%	9
Future Cardiology	Yes	N/A	9137	>70%	10
Future Microbiology	Yes	3.637	22,910	~50%	10
Future Neurology	No	N/A	4376	>80%	10
Future Oncology	Yes	2.129	34,450	~50%	10
Future Virology	No	0.886	5703	~50%	10
Hepatic Oncology	No	N/A	770	>80%	10
Immunotherapy	Yes	2.083	12,742	>70%	11
International Journal of Endocrine Oncology	No	N/A	551	>80%	11
International Journal of Hematologic Oncology	No	N/A	764	>80%	11
(NEW) Journal of 3D Printing in Medicine	No	N/A	N/A	N/A	7
Journal of Comparative Effectiveness Research	Yes	1.075	4508	~70%	11
Lung Cancer Management	No	N/A	1108	>80%	11
Melanoma Management	No	N/A	643	>80%	11
Nanomedicine	Yes	4.889	34,926	~40%	11
Neurodegenerative Disease Management	Yes	N/A	4823	>80%	12
Pain Management	Yes	N/A	5500	>80%	12
Personalized Medicine	No	1.00	5000	>60%	12
Pharmacogenomics	Yes	2.71	24,931	>80%	12
Regenerative Medicine	Yes	2.602	11,702	~50%	12

FUTURE SCIENCE AT-A-GLANCE

Journal	MEDLINE-indexed	Impact Factor (2015)	Average Abstract Views (per month)	Acceptance Rate (2016)	Page
Bioanalysis	Yes	2.813	57,836	>60%	14
Future Medicinal Chemistry	Yes	3.345	25,424	~50%	14
Future Science OA 	No	N/A	2432	>80%	14
(NEW) International Journal of Pharmacokinetics	No	N/A	N/A	N/A	7
Pharmaceutical Patent Analyst	Yes	N/A	3432	>80%	14
Therapeutic Delivery	Yes	N/A	9825	>80%	14

NEW TO FUTURE MEDICINE

Journal of 3D Printing in Medicine

Poised at the brink of an exciting new era in healthcare, The *Journal of 3D Printing in Medicine* encompasses all aspects of bioprinting and 3D printing of relevance to medicine. It will provide a forum for original research, review and commentary in this fast-moving, inter-disciplinary research area that promises new levels of precision, personalization and cost efficiency.

Frequency: 4 per year

Dietmar W Hutmacher
Editor-in-Chief




NEW TO FUTURE SCIENCE

International Journal of Pharmacokinetics

Original research studies and reviews addressing all issues relating to the preclinical and clinical pharmacokinetic study of potential therapeutics, serving the need of professionals within the field of drug development.

Frequency: 4 per year





Future Medicine
Journals

High-impact, high-quality journals

MI MEDLINE-indexed

IF Impact factor (2015)



MI IF 2.179

Biomarkers in Medicine

Frequency: 12 per year

Senior Editors:

Andre Terzic

Scott Waldman

Hot topics in all fields of medical biomarker research



Breast Cancer Management


Frequency: 4 per year

Senior Editors:

J Michael Dixon

V Craig Jordan

Provides cutting-edge research and management perspectives on this widespread disease



MI

CNS Oncology


Frequency: 4 per year

Senior Editors:

Alba A Brandes

Henry S Friedman

Clinical and translational research on, and management of, tumors of the central nervous system




Colorectal Cancer

Frequency: 4 per year

Senior Editor:

Heinz-Josef Lenz

Presents reviews, analysis and expert commentary on developments in this fast-moving field



Concussion

Rolling publication

The first international, open access journal to focus on this fast-developing field



MI IF 4.044

Epigenomics

Frequency: 12 per year

Senior Editors:

James G Herman

Jörg Tost

Focus on the description and analysis of epigenetic changes across the genome and their role in health and disease

Information needs in clinical and translational medicine and the biosciences



MI

Future Cardiology

Frequency: 6 per year

Covers advances in basic, translational and clinical cardiology research



MI IF 3.637

Future Microbiology

Frequency: 16 per year

Senior Editors:
Richard A Calderone
B Brett Finlay

Covers medical microbiological areas including all pathogen types and microbe–host interactions



Future Neurology

Frequency: 4 per year

Senior Editor:
Steven R Levine

Includes advances in basic, translational and clinical neurology research



MI IF 2.129

Future Oncology

Frequency: 30 per year

Senior Editors:
Ron Allison
Alan Dicker

Provides updates on oncology research, ranging from the bench to the bedside



IF 0.886

Future Virology

Frequency: 12 per year

Senior Editor:
Mark Wainberg

Latest updates in virology, infectious disease and immunology analysis



Hepatic Oncology

Frequency: 4 per year

Senior Editor:
Richard S Finn

Addresses all types of cancer of the liver, in both the adult and pediatric populations



MI IF 2.083

Immunotherapy

Frequency: 16 per year

Senior Editors:


Yutaka Kawakami

Francesco M Marincola

Kwong Tsang

David C Wraith

Therapeutics that harness the immune system to combat disease



International Journal of Hematologic Oncology

Frequency: 4 per year

Senior Editor:

Michele Baccarani

Discussion and analysis of emerging advancements in the management of blood cancers



MI IF 1.075

Journal of Comparative Effectiveness Research


Frequency: 8 per year

Senior Editors:

Sheldon Greenfield

Eugene C Rich

The only MEDLINE-indexed journal focused specifically on comparative effectiveness research



Melanoma Management


Frequency: 4 per year

Senior Editors:

Kevin B Kim

John Thompson

Focuses on clinical aspects of treating a patient with melanoma



International Journal of Endocrine Oncology

Frequency: 4 per year

Senior Editors:

Electron Kebebew

Karel Pacak

Specific focus on cancers of the endocrine system




(NEW) Journal of 3D Printing in Medicine

Editor-in-Chief

Dietmar W Hutmacher

Encompasses all aspects of bioprinting and 3D printing of relevance to medicine. See P.7.



Lung Cancer Management

Frequency: 4 per year

Editor-in-Chief:

David J Sugarbaker

Recent research findings and advances in clinical practice in lung cancer



MI IF 4.889

Nanomedicine

Frequency: 24 per year

Senior Editors:


Kostas Kostarelos

Charles R Martin

Advances in medical nanoscale-structured material and devices

“Professional staff, fast publication process. Highly recommended.”

– Ming Li, Biogen, USA



MI

Neurodegenerative Disease Management

Frequency: 6 per year

Associate Editors:

Anthony Schapira

Bruno Dubois

Managing neurodegenerative disease in practice



MI

Pain Management

Frequency: 6 per year

Senior Editor:

Martin Grabis

Latest research findings and reviews in pain medicine



IF 1.00

Personalized Medicine

Frequency: 6 per year

Editors:

Edward Abrahams

Geoffrey Ginsburg

Howard L McLeod

Cutting-edge advances in precision medicine are put into a clinical context alongside arising ethical, policy and regulatory issues



MI

IF 2.71

Pharmacogenomics

Frequency: 18 per year

Senior Editors:

David Gurwitz

Howard McLeod

Research and comment on the role of genomics in drug response



MI

IF 2.602

Regenerative Medicine

Frequency: 8 per year

Senior Editor:

Chris Mason

Up-to-date research for the translation of regenerative medicine from bench to bedside

Applied science and intellectual property issues in R&D



MI IF 2.813

Bioanalysis

Frequency: 24 per year

Senior Editor:

Neil Spooner

Scientific, technical and regulatory developments in bioanalysis



MI IF 3.345

Future Medicinal Chemistry

Frequency: 18 per year

Senior Editors:

Jonathan Baell

Iwao Ojima

Design of small-molecule bioactive agents and the identification of therapeutic targets



Future Science OA

Rolling Publication

Senior Editors:


Benoit Arsenaux

Ian A Blair

Paul N Span



High-quality Gold Open Access journal, covering all research of relevance to human health



(NEW) International Journal of Pharmacokinetics

Editors:


Karel Allegaert

Jasper Dingemans

Nuggehally R Srinivas

Raman Venkataraman

Original research studies and reviews addressing all issues relating to the preclinical and clinical pharmacokinetic study of potential therapeutics. See P.7.



MI

Pharmaceutical Patent Analyst

Frequency: 6 per year

Senior Editors:

Lyn Jones

Andrew McKnight

David Rotella

High-impact scientific reviews of recent patents, discussed within the context of other R&D advances



MI


Therapeutic Delivery

Frequency: 12 per year


Comprehensive coverage of all aspects of the evolving drug delivery field

Diverse audience

FUTURE MEDICINE



FUTURE SCIENCE



Abstracted and indexed
in all the main databases

INFORMATION FOR LIBRARIANS

INSTITUTIONAL & ACADEMIC SUBSCRIPTIONS

Academic pricing is set regardless of size or number of sites. All academic institutes receive 5 years of content.

CORPORATE

Corporate pricing is dependent on the size of the company and the number of sites. Corporate institutes receive 2 years of content (backfills of content are available upon request).

CONSORTIA

FSG works with consortia of various types and sizes and welcomes discussion with all consortium managers. COUNTER-compliant usage statistics are provided for each institution. The benefits for the consortium include discounts on list price. Members have the flexibility to select the publications they want to include, or FSG will work with the consortium to create customized packages.

INDEXING

FSG titles are abstracted and indexed in all the main databases including MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Scopus, Thomson's Science Citation Index Expanded and Chemical Abstracts.

Services

- Flexible purchasing
- Accessible for all institution types
- COUNTER-compliant usage reports
- ATHENS & Shibboleth authentication compliant
- Reliable publishing platform
- Dynamic customer services
- Promotion tools upon request
- Collection leasing

INSTITUTIONAL TRIALS

If you would like to trial our content, just get in touch. Trials can be on single publications or entire collections, the choice is yours. We will work with you to decide on the best time and duration for your institution.

During the trial period, you have:

- Full-text access to the titles you select
- Detailed usage statistics from our Atypon-backed platform
- Support from our in-house technical team
- Control over the duration, visibility and promotion of the trial

Fair usage limits apply. For more details speak to a member of our team.

To request trial access,
contact us at:

trials@future-science-group.com
or on +44 (0)20 8371 6090

Services



NEW WEBSITE

Our new fully responsive site ensures all users will have the same reader experience no matter which device they use. Plus, the new, intuitive interface and streamlined navigation will reduce the number of clicks needed for readers to reach their desired content. We're sure our improvements will encourage all users to return even more frequently.

Future Medicine
The Bologna experience with the Thoraflores™ hybrid frozen elephant trunk device

Roberto Di Bartolomeo¹, Luca Di Matteo¹, Alessandro Lorenzini¹, Antonio Pantalone¹, Marco Di Eusanio¹, Giuseppe Barberio¹ & Davide Fucini¹

Abstract

Background: We present our initial experience with the frozen elephant trunk using a Thoraflores™ hybrid device for the treatment of the complex thoracic aortic disease. **Materials & Methods:** Between March 2013 and March 2014, 14 patients underwent thoracic aortic surgery using the frozen elephant trunk approach with the Thoraflores hybrid device. **Indications for surgery were:** ascending aortic aneurysm (eleven patients), degenerative aortic aneurysm (three patients) and Bicuspid aortic valve (four patients). **Results:** In-hospital mortality was 0%. In-hospital permanent paraplegia, paraparesis or major neurological events, one patient experienced moderate chronic attack. **Conclusion:** Our initial experience demonstrated excellent early results. The Thoraflores hybrid approach with the frozen elephant trunk increases the spectrum of endovascular available for the surgeon in the treatment of complex disease of the thoracic aorta.

The surgical treatment of diffuse pathologies of the thoracic aorta remains a challenging issue in aortic surgery. Classically, they are treated with the open approach known as the "frozen elephant trunk" procedure. However, a hybrid (endovascular and endovascular treatment with conventional surgery, the so-called "frozen elephant trunk" (FET) technique^{1,2}), has been described as an endovascular approach. Several authors reported encouraging results with this technique in aortic and thoracic aortic disease³⁻⁵. Thoraflores™ hybrid devices are available: the 4-stake open type (Thoraflores™, Germany) and the Thoraflores™ Covered FET (hybrid device). Our early experience with the FET technique using the Thoraflores™ hybrid device is presented in this article.

Materials & methods

- **Patient profile:** Between January 2009 and March 2014, a total of 148 patients with complex pathology of the thoracic aorta were treated with the FET procedure in our institution. Aqurate Institutional Review Board approval has been obtained.
- **Study protocol:** This retrospective study included 101 patients (70.3% of Thoraflores hybrid device cases). There were 50 men (49.5%) and 51 (50.5%) were female. The mean age was 52.4 ± 9 years (range, 31–78 years). Aortic hypoflexion (nine patients, 8.9%), chronic aortic aneurysm (eight patients, 8.9%), and smoking history (three patients, 3.0%) were the main factors. There were no patients with degenerative chronic total aortic occlusion.

Indications for surgery included: ascending aorta aneurysm in eight patients (80%), chronic aneurysm of the distal arch in one patient, and chronic type B dissection in one patient.

- **Hybrid endovascular device**

The Thoraflores™ Thoraflores™ hybrid device is composed of a proximal trunk (covered) woven polyester prosthesis coupled to a distal covered stent graft. The proximal portion of the stent graft is fixed to the aorta with the following characteristics:

YOU MIGHT ALSO LIKE

Future Medicine | HOME

REGISTER | LOGIN | CART

JOURNALS | **eBOOKS** | **MOST READ** | **MOST CITED** | **TOPICS**

Biomarkers in Medicine
Breast Cancer Management
Clinical Lipidology
CNS Oncology
Concussion
Colorectal Cancer
Colorectal Cancer See all v

Histoplasma capsulatum, Lung Infection and Immunity
Harwell M et al.
Future Medicine | 10.1093/fm/...
Update and current status of diffusion weighted imaging...
Review D
Future Med | Vol. 2, No. 1
Measuring brain iron levels as a marker of ADHD.
Thomas L
Future Med | Vol. 12, No. 2

FSG Interviews Sangeev Nayak,
Consultant Neurologist,
University Hospital of North,
Mitlans, UK

Share science socially, follow us

FOR AUTHORS | **FOR LIBRARIANS** | **ADVERTISING** | **SUBSCRIPTIONS**

Upholding the highest standards
of editorial expertise and integrity

OUR PUBLISHING PROCESS

FSG upholds the highest standards of editorial integrity, including disclosure and independent peer review. We adhere to the guidelines set by COPE and ICMJE, endorse CONSORT, and follow the recommendations set by GPP3, ensuring our authors and readers are in safe hands.

Our unique editorial model, with an in-house, London-based team, means there is a specialist point of contact available at all times. This makes it easy for you to reach an expert in your field, understand the potential of your research and work towards achieving your objectives, with each author receiving the support of a dedicated editor.

Our publishing process is reassuringly rigorous, with a minimum of three experts (one in-house specialist editor and a minimum of two external) reviewing each paper.



EDITORIAL BOARDS

All journals are supported through guidance from their Editorial Boards.

Our Editorial Board members represent the world's most prestigious organizations, including:

- Cambridge University, UK
- Harvard University, USA
- Monash University, Australia
- Karolinska Institute, Sweden
- Kyoto University, Japan
- Cancer Research UK, UK

A global network of researchers, practitioners and policy makers

READERSHIP

Our journal readership spans specialists in bioscience and medical practice across the globe.

Our key reader groups are:

- **Clinical, basic and translational researchers** in academia, industry, hospitals and government research organizations
- **Clinicians in primary and secondary care**, including: cardiologists, neurologists and oncologists
- **Policy and decision makers** in government and industry
- Those with an interest in **pharmaceutical patents/ intellectual property**


FUTURE MEDICINE

www.futuremedicine.com

25 journals

Last 12 months*:

- 2.7 million abstract views
- 833,000 full-text downloads
- Global coverage




FUTURE SCIENCE

www.future-science.com

6 journals

Last 12 months*:

- 1.2 million abstract views
- 349,000 full-text downloads
- Global coverage



*as of June 30, 2016

MAKING THE MOST OF YOUR ARTICLE

MAXIMIZING YOUR RESEARCH

Whether you're looking to publish clinical trial results, describe the design of a new study or provide an in-depth review, our team will support you fully before, during and after publication.

We are happy to work with both academic key opinion leaders as well as industry authors, as we recognize they are also among the leading experts in their field.

In addition to offering presubmission advice, we will assist you with journal selection for a broad range of article types, including:

ORIGINAL RESEARCH

- Pre- and post-registration studies
- Comparative effectiveness research
- Observational studies
- Clinical trial methodologies
- Cost-effectiveness/HEOR studies
- Negative data
- Evidence-based medicine and real-world data

REVIEWS

- Narrative reviews
- Unmet medical needs
- Multidisciplinary approaches to care
- Consensus and treatment guidelines
- Management perspectives
- Therapeutic overviews
- Drug, device and vaccine evaluations
- Commentaries on key clinical studies
- Systematic reviews

More exposure
for quality research

OPEN ACCESS

Publishing an article Open Access increases the readers it is able to reach, along with the recognition for you and your organization.

Open Access articles have significantly higher readership and usage than articles behind the subscription barrier.

All FSG subscription journals offer an Open Access option. FSG also publishes two fully Open Access journals – *Concussion* (P.9) and *Future Science OA* (P.14).

Authors can opt for our Gold Open Access option (CC BY-NC-ND), allowing unrestricted access to the online version of their article. This option is available for all article types except Drug Evaluation and Device Evaluation articles. We also offer reduced pricing for articles 12 months or older. For more information about pricing, contact j.walker@future-science-group.com

Get vital content published
within 6 weeks


ACCELERATED PUBLICATION

Our typical publication times are 14 to 16 weeks as standard (pending successful peer review).

But if you require earlier publication, you can publish in as little as 6 weeks through our Accelerated Publication service.

Accelerated Publication could help you stay ahead of the competition, or allow you to get some vital content out before an important conference. It will maximize the impact of your scientific endeavor, ensuring swifter access to your latest findings.

A fee per published page applies, and publication is, of course, still subject to approval by independent peer review.



Encourage readers to access and engage with your research

ENAGO

We partner with Enago to offer pre-submission editing services, including English editing and proofreading of scientific manuscripts for authors for whom English is a second language. For further information please contact our Editorial Director Laura Dormer at l.dormer@future-science-group.com. Or go to <http://futuremedicine.enago.com> <http://futurescience.enago.com>

KUDOS

All of our journals are available on the Kudos platform, a web-based service that helps researchers and their institutions and funders to maximize the visibility and impact of their published articles. Kudos provides a platform for assembling and creating information to help search filtering, for sharing information to drive discovery, and for measuring and monitoring the effect of these activities.

SPONSORED ACCESS

Sponsors or third parties wishing to make an article free to download from our website can provide access by paying the appropriate Sponsored Access fee. More information on the Sponsored Access option is available upon request.

“I would highly recommend submitting high-quality scientific manuscripts to [FSG’s] peer-reviewed journals.”

– Starr Grundy, Founding Partner, SD Scientific, USA

SUPPLEMENTS

Supplements are an ideal way to provide focused, added-value content for your target audience. Content may comprise:

- Symposia proceedings
- Abstract compilations
- Workshop summaries
- Roundtable discussions
- Article collections

All supplements follow the same standards of editorial integrity adopted by our journals, including disclosure, independent peer-review and publication guideline adherence (ICMJE/GPP3). Publication times are flexible depending on your needs and supplements can be published as early as 4 weeks from acceptance.

REPRINTS

Our dedicated in-house account managers are available throughout the publication process to discuss the dissemination of your research.

Reprints and ePrints are available in quantities as few as 100 copies, and we can customize them to include bespoke covers, logos and legal disclaimers.

We can deliver reprints to multiple locations worldwide, translating them into any language you require.

DIGITAL SOLUTIONS

To help meet your goals, we can enrich your research with digital options on our web platforms including:

- Audio/video abstracts
- Graphical abstracts
- Infographics and article snapshots
- Mechanism of action videos

Enhancing the value of our publications, we also have online networks, featuring journal articles as well as expert interviews and bespoke content. By featuring your article on our eCommunity sites you can further your reach to highly engaged groups. For more details on our eCommunities go to P.30.

“I have worked with FSG several times and have been consistently impressed with the positive experience.”

– Professor Giorgio Mustacchi, Università degli Studi di Trieste, Italy

SOCIAL MEDIA

All of our journals are integrated with Twitter, and many of our journals have sizable LinkedIn groups.

To maximize the impact of your article we can target niche groups with content exclusively devoted to your work.



ARTICLE METRICS



Leveraging both the Altmeter and Atypon platforms, we are able to provide granular article-level metrics for all our articles. Authors can look at the conversations around their paper and request usage data, making it easy for them to measure the impact and reach of their article.

HOW TO PUBLI

Presubmission enquiries welcome

j.walker@future-science-group.com



Enago



Article submitted

Author revisions




Article ready for submission

Peer-review




Don't forget!

You will need a signed author disclosure form,  and a signed copyright form/OA license form

online



PUBLISH WITH FSG



eCommunities



Niche communities that facilitate collaboration and innovation

eCOMMUNITIES

Our eCommunities are built to meet the specific needs of niche scientific and medical communities. Enriched with high-value expert insight and integration with social media, our websites enhance the value of our publications.

Bioanalysis Zone, Oncology Central and Neurology Central have their own apps offering users personalized content from the past 30 days, including the latest news, journal articles and video in their field. This allows users to be specific about the topics they want to see, and to only receive the content notifications that really matter to them.

For more information about any of our eCommunities, contact r.hill@future-science-group.com




Bioanalysis Zone
www.bioanalysis-zone.com

With over 8000 registered users, Bioanalysis Zone is the market-leading online resource for the global bioanalytical community.

Bioanalysis Zone features an App.

Associated publication:

Bioanalysis
(MEDLINE-indexed, IF 2.813)



Bringing scientific and medical professionals together



Oncology Central
www.oncology-central.com


Oncology Central offers easy access to breaking news and peer-reviewed articles in a clinician-curated environment.

Membership includes access to the peer-reviewed journals: *Breast Cancer Management*, *CNS Oncology*, *Colorectal Cancer*, *Hepatic Oncology*, *International Journal of Endocrine Oncology*, *International Journal of Hematologic Oncology*, *Lung Cancer Management* and *Melanoma Management*.

Oncology Central features an App.

Other associated publications:

Epigenomics
(MEDLINE-indexed, IF 4.044)
Future Oncology
(MEDLINE-indexed, IF 2.129)
Immunotherapy
(MEDLINE-indexed, IF 2.083)



Neurology Central
www.neurology-central.com

Uniting all aspects of neurology, Neurology Central provides a high-quality platform that makes it easy to stay up-to-date with the latest developments in the field.

Membership includes access to the peer-reviewed journals: *CNS Oncology*, *Concussion*, *Future Neurology*, *Neurodegenerative Disease Management* and *Pain Management*.

Neurology Central features an App.

Connect, collaborate
and discover

MedChemNet

MedChemNet
www.medchemnet.com

Bringing together medicinal chemistry professionals to discuss the latest research in this field, MedChemNet delivers news updates and features input from influential leaders, while acting as a platform for medicinal chemists to have their voices heard.

Associated publications:



Future Medicinal Chemistry
(MEDLINE-indexed, IF 3.345)

Pharmaceutical Patent Analyst

(MEDLINE-indexed)

Therapeutic Delivery

(MEDLINE-indexed)



EpiGenomicsNet

EpiGenomicsNet
www.epigenomicsnet.com

The only network of its kind providing focused content and a platform for informative discussion on this cutting-edge subject.

Associated publications:

Biomarkers in Medicine
(MEDLINE-indexed, IF 2.179)

Epigenomics
(MEDLINE-indexed, IF 4.044)

Personalized Medicine
(IF 1.00)

Pharmacogenomics
(MEDLINE-indexed, IF 2.71)

RegMedNet

RegMedNet
www.regmednet.com

RegMedNet provides a unique and unparalleled platform for the regenerative medicine community to share insights, discuss the latest research, and help move this pioneering field forward.



Associated publication:
Regenerative Medicine
(MEDLINE-indexed, IF 2.602)

3DMedNet

3DMedNet
www.3dmednet.com

From regulators and manufacturers to surgeons and bioengineers, 3DMedNet is a network that unites all members of this diverse community, enabling the connection and collaboration to help this exciting field move forward at an even faster rate.

Associated publication:
Journal of 3D Printing in Medicine (New in 2016)



“A big factor in making our webinar successful was the promotion and willingness of FSG to try new ideas to push registrations up.”

— Marketing Communications Manager, Thermo Fisher Scientific

SPONSORSHIP & ADVERTISING

There are now so many opportunities to communicate with people it is sometimes hard to know the most effective way to reach your particular target audience. At FSG, we offer our genuine insight into scientific communities to help you make sure your campaign reaches the right people in the right way.

Every project begins with an understanding of your goals. With our broad portfolio of journals, eCommunities and client opportunities we then create personalized and targeted campaigns that focus on your potential customers. With our in-house editorial and design teams we can offer you dedicated support to make sure the optimal message is delivered.

We want your campaign to be a success and know how important it is to be able to define your ROI; with this in mind we provide a detailed analytics report for every project we undertake to help you justify your marketing spend and plan your future campaigns.

For Bioanalysis Zone and MedChemNet enquiries, please contact:

Sarah Bishop at:

s.bishop@future-science-group.com

For all other eCommunity enquiries as well as journal sponsorship and advertising opportunities, please contact:

Andy Kemp at:

a.kemp@future-science-group.com

Sponsorship opportunities include:

- Webinars
- Sponsored audio and video recordings
- Product and company listings
- Symposia, conference reports and special issues
- Article reprints
- Sponsored access
- Sponsored subscriptions
- Targeted advertising placements
- Expert interviews and opinion
- Spotlights
- Surveys and polls

Contact us

For more information about our services contact:
j.walker@future-science-group.com

For more information about our journals or eCommunities contact:
info@future-science-group.com

For more information about institutional trials contact:
trials@future-science-group.com

Future Science Group

Unitec House
2 Albert Place
London, N3 1QB
United Kingdom

 +44 (0)20 8371 6090

 info@future-science-group.com

 www.future-science-group.com

 [@futuresciencegp](https://twitter.com/futuresciencegp)